VIREAD 300 MG
TENOFOVIR DISOPROXIL FUMARATE : 300 MG · DIN 02247128 · GILEAD SCIENCES CANADA INC
Health Canada status: MARKETED
What is VIREAD?
VIREAD 300 MG contains TENOFOVIR DISOPROXIL FUMARATE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02247128, held by GILEAD SCIENCES CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 21-May-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VIREAD used for?
VIREAD (tenofovir disoproxil fumarate [TDF]) is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients 12 years of age and older. VIREAD is indicated for the treatment of chronic hepatitis B infection in patients 18 years of age and older, with compensated liver disease, with evidence of active viral replication, with elevated serum alanine aminotransferase (ALT) levels or evidence of fibrosis (based on liver biopsy or a noninvasive procedure); evidence of lamivudine-resistant hepatitis B virus; or decompensated liver disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02247128 |
|---|---|
| Brand name | VIREAD |
| Generic / active ingredient | TENOFOVIR DISOPROXIL FUMARATE : 300 MG |
| Manufacturer | GILEAD SCIENCES CANADA INC |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AF07 TENOFOVIR DISOPROXIL |
| AHFS class | 08:18.08.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-May-2009 |
| Original market date | 2004-03-15 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is TENOFOVIR DISOPROXIL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SIVEM PHARMACEUTICALS ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J05AF07 TENOFOVIR DISOPROXIL. 13 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-TENOFOVIR | 300 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02516276 |
| APO-TENOFOVIR | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 02451980 |
| AURO-TENOFOVIR | 300 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02460173 |
| JAMP-TENOFOVIR | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02479087 |
| MINT-TENOFOVIR | 300 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02512939 |
| MYLAN-TENOFOVIR DISOPROXIL | 300 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02452634 |
| NAT-TENOFOVIR | 300 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02472511 |
| PMS-TENOFOVIR | 300 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02453940 |
| RIVA-TENOFOVIR | 300 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 02515156 |
| TENOFOVIR | 300 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02523922 |
Who else supplies TENOFOVIR DISOPROXIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TENOFOVIR DISOPROXIL appears in 726 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.